Literature DB >> 31913193

Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: Results of a Nationwide Population-Based Study.

Eric D Shah1, Christopher V Almario2, Brennan M Spiegel2, William D Chey3.   

Abstract

INTRODUCTION: Abdominal pain is a cardinal feature of irritable bowel syndrome (IBS); however, differences in abdominal pain among IBS subtypes remain unknown. We aimed to characterize abdominal pain symptoms among established IBS subtypes using data from the National Gastrointestinal (GI) Survey.
METHODS: Individuals participating in the National GI Survey completed National Institutes of Health GI Patient-Reported Outcomes Measurement Information System (GI-PROMIS) questionnaires. Adults meeting modified Rome III IBS criteria and reporting abdominal pain in the previous 7 days were eligible. Outcomes included abdominal pain severity, bothersomeness, interference with daily activities, frequency, and location. Results were stratified by subtype (diarrhea [IBS-D], constipation [IBS-C], and mixed [IBS-M]). Regression models adjusted for demographics and comorbidities.
RESULTS: One thousand one hundred fifty-eight individuals (245 IBS-D, 232 IBS-C, and 681 IBS-M) with active IBS symptoms (defined as abdominal pain in the past 7 days) were included. Demographics were similar among the subtypes except for age, race/ethnicity, education, and marital status. The GI-PROMIS score was lower for IBS-D (percentile score of 68.6, SD = 25.1; P = 0.001) and IBS-M (69.1, SD = 25.1; P < 0.001) compared with IBS-C (75.5, SD = 20.7). Abdominal pain was more bothersome (P = 0.001), caused more interference with daily activities (P = 0.03), and was more frequent (P = 0.047) for individuals with IBS-C compared with individuals with IBS-D. No differences in these domains were seen between individuals with IBS-D and IBS-M. Individuals with IBS-C and IBS-M had more widespread pain compared with those with IBS-D. DISCUSSION: In this population-based study, we found that abdominal pain characteristics differ between the IBS subtypes. Namely, individuals with IBS-C experience more bothersome, frequent, and diffuse abdominal pain compared with those with IBS-D.

Entities:  

Mesh:

Year:  2020        PMID: 31913193      PMCID: PMC7469977          DOI: 10.14309/ajg.0000000000000502

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   12.045


  39 in total

1.  Prevalence of and Factors Associated With Fecal Incontinence: Results From a Population-Based Survey.

Authors:  Stacy B Menees; Christopher V Almario; Brennan M R Spiegel; William D Chey
Journal:  Gastroenterology       Date:  2018-02-03       Impact factor: 22.682

Review 2.  Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report.

Authors:  Douglas A Drossman; Jan Tack; Alexander C Ford; Eva Szigethy; Hans Törnblom; Lukas Van Oudenhove
Journal:  Gastroenterology       Date:  2017-12-22       Impact factor: 22.682

3.  Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

Authors:  Joel Castro; Andrea M Harrington; Patrick A Hughes; Christopher M Martin; Pei Ge; Courtney M Shea; Hong Jin; Sarah Jacobson; Gerhard Hannig; Elizabeth Mann; Mitchell B Cohen; James E MacDougall; Bernard J Lavins; Caroline B Kurtz; Inmaculada Silos-Santiago; Jeffrey M Johnston; Mark G Currie; L Ashley Blackshaw; Stuart M Brierley
Journal:  Gastroenterology       Date:  2013-08-16       Impact factor: 22.682

4.  Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans.

Authors:  Christopher V Almario; Megana L Ballal; William D Chey; Carl Nordstrom; Dinesh Khanna; Brennan M R Spiegel
Journal:  Am J Gastroenterol       Date:  2018-10-15       Impact factor: 10.864

5.  Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS.

Authors:  Ashok Attaluri; Michelle Jackson; Jessica Valestin; Satish S C Rao
Journal:  Am J Gastroenterol       Date:  2009-12-01       Impact factor: 10.864

6.  Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin.

Authors:  Chander Shekhar; Phillip J Monaghan; Julie Morris; Basma Issa; Peter J Whorwell; Brian Keevil; Lesley A Houghton
Journal:  Gastroenterology       Date:  2013-07-19       Impact factor: 22.682

7.  Inflammatory cell distribution in colon mucosa as a new tool for diagnosis of irritable bowel syndrome: A promising pilot study.

Authors:  J Boyer; M-C Saint-Paul; B Dadone; S Patouraux; M-H Vivinus; D Ouvrier; J-F Michiels; T Piche; M K Tulic
Journal:  Neurogastroenterol Motil       Date:  2017-10-04       Impact factor: 3.598

8.  Are characteristics of abdominal pain helpful to identify patients with visceral hypersensitivity in irritable bowel syndrome? Results of a prospective study.

Authors:  C Melchior; L Bril; A-M Leroi; G Gourcerol; P Ducrotté
Journal:  Neurogastroenterol Motil       Date:  2018-01-18       Impact factor: 3.598

9.  The intestinal barrier in irritable bowel syndrome: subtype-specific effects of the systemic compartment in an in vitro model.

Authors:  Samefko Ludidi; Daisy Jonkers; Elhaseen Elamin; Harm-Jan Pieters; Esther Schaepkens; Paul Bours; Joanna Kruimel; José Conchillo; Ad Masclee
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

10.  Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.

Authors:  Eric D Shah; Christopher V Almario; Brennan M R Spiegel; William D Chey
Journal:  J Neurogastroenterol Motil       Date:  2018-04-30       Impact factor: 4.924

View more
  8 in total

Review 1.  Pain in irritable bowel syndrome: Does anything really help?

Authors:  Joelle BouSaba; Wassel Sannaa; Michael Camilleri
Journal:  Neurogastroenterol Motil       Date:  2021-12-03       Impact factor: 3.960

2.  Whole Body Pain Distribution and Risk Factors for Widespread Pain Among Patients Presenting with Abdominal Pain: A Retrospective Cohort Study.

Authors:  Jennifer M Hah; Vasiliki I Aivaliotis; Gabrielle Hettie; Luke X Pirrotta; Sean C Mackey; Linda A Nguyen
Journal:  Pain Ther       Date:  2022-04-25

3.  Baseline Predictors of Discontinuation of Prescription Drug Therapy for IBS-C: Cohort Analysis at an Integrated Healthcare System.

Authors:  Eric D Shah; Darren M Brenner; Vincent L Chen
Journal:  Dig Dis Sci       Date:  2021-03-29       Impact factor: 3.199

4.  Mechanism of dexmedetomidine preconditioning on spinal cord analgesia in rats with functional chronic visceral pain.

Authors:  Jun Li; Huizhong Tang; Weifeng Tu
Journal:  Acta Cir Bras       Date:  2022-05-02       Impact factor: 1.564

Review 5.  Impact of Diet on Symptoms of the Irritable Bowel Syndrome.

Authors:  Robin Spiller
Journal:  Nutrients       Date:  2021-02-09       Impact factor: 5.717

6.  Aloe barbadensis Mill. extract improves symptoms in IBS patients with diarrhoea: post hoc analysis of two randomized double-blind controlled studies.

Authors:  Bani Ahluwalia; Maria K Magnusson; Lena Böhn; Stine Störsrud; Fredrik Larsson; Lena Öhman; Magnus Simrén
Journal:  Therap Adv Gastroenterol       Date:  2021-10-08       Impact factor: 4.409

7.  Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation.

Authors:  Florian Mourey; Amélie Decherf; Jean-François Jeanne; Mathieu Clément-Ziza; Marie-Lise Grisoni; François Machuron; Sophie Legrain-Raspaud; Arnaud Bourreille; Pierre Desreumaux
Journal:  World J Gastroenterol       Date:  2022-06-14       Impact factor: 5.374

8.  Abdominal Pain Severity Is Mainly Associated with Bloating Severity in Patients with Functional Bowel Disorders and Functional Abdominal Pain.

Authors:  David Deutsch; Michel Bouchoucha; Julien Uzan; Jean-Jacques Raynaud; Jean-Marc Sabate; Robert Benamouzig
Journal:  Dig Dis Sci       Date:  2021-07-29       Impact factor: 3.487

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.